MedPath

Early Recognition and Dynamic Risk Warning System of Multiple Organ Dysfunction Syndrome Caused by Sepsis

Recruiting
Conditions
Sepsis
MODS
Registration Number
NCT04904289
Lead Sponsor
Sun Yat-sen University
Brief Summary

Background Sepsis still the main challenge of ICU patients, because of its high morbidity and mortality. The proportion of sepsis, severe sepsis, and septic shock in china were 3.10%, 43.6%, and 53.3% with a 2.78%, 17.69%, and 51.94%, of 90-day mortality, respectively.

Besides, according to the latest definition of sepsis- "a life-threatening organ dysfunction caused by a dysregulated host response to infection. ", it is a disease with intrinsic heterogeneity. Sepsis as a syndrome with such great heterogeneity, there will be significant differences in the severity of sepsis. As a result, there will be significant differences in the treatment and monitoring intensity required by patients with severe sepsis and mild sepsis. No matter from the economic perspective or from the risk of treatment, a proper level of treatment will be the best chose of patient. However, the evaluation of the sepsis severity was not satisfied. Such of SOFA, the AUC of predict patients' mortality was only 69%. Weather these patients occurred multiple organ dysfunction syndrome (MODS) may had totally different outcome and needed totally different treatment. All these treatments need early interference, in order to achieve a good prognosis. Hence, early recognition of MODS caused by sepsis became an imperious demand.

Study design On the base of regional critical medicine clinical information platform, a multi-center, sepsis big data platform (including clinical information database and biological sample database) and a long-term follow-up database will be established. Thereafter, an early identification, risk classification and dynamic early warning system of sepsis induced MODS will be established. This system was based on the real-time dynamic vital signs and clinical information, combined with biomarker and multi-omics information. And this system was evaluated sepsis patients via artificial intelligence, machine learning, bioinformatics analysis techniques.

Finally, optimize the early diagnosis of sepsis induced MODS, standardized the treatment strategy, reduce the morbidity and mortality of MODS through this system.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
60000
Inclusion Criteria
  • Patients diagnosed with sepsis3.0
Exclusion Criteria
  • Patients' data missing is greater than 20%

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Sensitivity of the MODS recognized system90 days
Specificity of the MODS recognized system90 days
The AUC of the MODS recognized system ROC90 days
Secondary Outcome Measures
NameTimeMethod
The mortality of MODS in sepsis patients90 days

The mortality of MODS in Chinese sepsis patients

The Incidence rate of MODS in sepsis patients90 days

The Incidence rate of MODS in Chinese sepsis patients

Trial Locations

Locations (18)

Chinese PLA General Hospital

🇨🇳

Beijing, Beijing, China

Peking Union Medical College Hospital

🇨🇳

Beijing, Beijing, China

Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University

🇨🇳

Guangzhou, Guangdong, China

The First Affiliated Hospital of Guangzhou Medical University

🇨🇳

Guangzhou, Guangdong, China

The First Affiliated Hospital, Sun Yat-sen University

🇨🇳

Guangzhou, Guangdong, China

Qingyuan People's Hospital

🇨🇳

Qingyuan, Guangdong, China

Peking University Shenzhen Hospital

🇨🇳

Shenzhen, Guangdong, China

Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology

🇨🇳

Wuhan, Hubei, China

Nanjing General Hospital of Nanjing Military Commend

🇨🇳

Nanjing, Jiangsu, China

The First Affiliated Hospital of Xi 'an Jiaotong University

🇨🇳

Xi'an, Shaanxi, China

Scroll for more (8 remaining)
Chinese PLA General Hospital
🇨🇳Beijing, Beijing, China
Zhou Feihu, M. D
Contact
zhoufh301@126.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.